The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights

Osteosarcoma, the most aggressive primary malignant bone tumor, has stagnant therapeutic outcomes despite decades of standard MAP chemotherapy and surgery; 5-year overall survival (OS) is <30% for metastatic/recurrent cases. Plagued by genomic heterogeneity, immunosuppressive TME, and low immunog...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Lifeng Ge, Tianhao Xu, Xiaodong Gu, Xuekang Pan, Tian Gao, Huigen Lu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2026-03-01
coleção:	Frontiers in Immunology
Assuntos:	alkylating agents anthracyclines anti-angiogenic agents antimetabolites apatinib CD8a
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2026.1790067/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!